Merck's Q3 2014 earnings call highlighted strong performance in key areas like diabetes and acute care, driven by JANUVIA and investments.  The KEYTRUDA launch, while still early, showed promising uptake.  However, some declines in vaccine sales and HCV portfolio, along with the divestment of consumer care, tempered overall revenue growth.  Overall, the near-term outlook appears positive, with the KEYTRUDA launch providing a significant driver.
[1]
